Allergan buyout Round 4: Ball's in Valeant's (hostile) court
This article was originally published in Scrip
Executive Summary
Allergan's board of directors voted unanimously to reject an almost $54bn acquisition offer by Valeant Pharmaceuticals as the board continues to favor Irvine, California-based Allergan's research and development strategy over Valeant's acquisition-based growth strategy.